Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mycophenolate mofetil adjunctive therapy for pemphigus vulgaris with reduced corticosteroid dosing
2004-000526-75Phase 3Completed
- Sponsor
- Aspreva Pharmaceuticals
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mycophenolate mofetil in pemphigus vulgaris (PV) (3 arms), sponsored by Aspreva Pharmaceuticals. Primary endpoint: Responder rate. Started Dec 2005; status: completed.
02
Drugs
mycophenolate mofetil
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on 2004-000526-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000526-75.